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Microcirculation impairment and related vasculopathy is a hallmark of systemic 
sclerosis. Digital ulcers are second only to Raynaud’s phenomenon as a vascular 
complication occurring in scleroderma patients. Digital ulcers are painful and 
generate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
disability. Furthermore, patients may develop recurrent digital ulcers and one may 
ask whether the outcomes of such patients might be different to those of unaffected 
ones. Recently several registries have provided relevant information about digital 
ulcers. Male sex and severe skin disease seem to be the main associated factors 
observed in several registries. However, the limitations in those studies are the 
differences with regards to the definitions of digital ulcers and of organ involvement. 
Few longitudinal studies are available and the more robust data from EUSTAR cohort 
suggest worse outcomes when a history of digital ulcers is present but could not 
demonstrate that it can predict additional vascular complications like pulmonary 
arterial hypertension, heart failure or renal crisis. Nevertheless, the old autopsy 
studies and the more recent biomarker longitudinal studies support the concept of 
generalized vasculopathy and a potential association between various cardiovascular 
complications. It is expected that with the availability of several structured registries, 
the question about the identification of a vascular profile, or vascular phenotype, will 
be addressed using more robust data in a near future.   
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Systemic sclerosis (SSc) is an autoimmune connective tissue disorder that is 
characterized by a complex interplay of vascular abnormalities, immune system 
activation and an uncontrolled fibrotic response. Vascular component is often 
referred to as vasculopathy and is seen as having a key role in the early 
pathogenesis of SSc. Patients with SSc develop a broad spectrum of vascular 
manifestations including the almost universal Raynaud’s phenomenon (distal 
vasospasm), commonly digital ulceration and more rarely critical digital ischaemia. In 
parallel, within this very heterogeneous disease, some patients will develop vascular 
related organ damages leading to heart or kidney failure 1-3. It is still unclear 
whether there is a continuum between peripheral vasculopathy promoting digital 
ulceration (DU), or critical ischemia, and some other vascular related complications 
4, 5. The objective of this article is to address this question by analysing whether 
severe digital vasculopathy could be a surrogate for vasculopathy elsewhere. The 
various sources of information to answer this research question are shown on figure 
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GENERALIZED MICROVASCULAR DAMAGE: from Raynaud’s to obliterated 
small vessels                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
SSc vasculopathy depends on the complex interaction of various pathological 
processes including autoimmunity, impaired compensatory vasculogenesis, and 
angiogenesis, endothelial-mesenchymal transition (EMT), endothelial dysfunction, 
and impaired coagulation/fibrinolysis system. SSc vasculopathy is characterized by a 
variety of such changes that affect primarily the microcirculation and small arterioles 
4,5. Larger vessel disease can occur in SSc 6, although there are still some 
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debates about the risk of atherosclerosis in SSc 7. This topic is beyond the scope of 
our article that looks primarily at the potential risk of generalized microangiopathy 
and a potential continuum between digital ulcers and organ based vasculopathy. 
The hallmark of functional abnormalities related to SSc vasculopathy is Raynaud’s 
phenomenon (RP). It is characterized by exaggerated but reversible vasospasm in 
response to cold exposure, stress, or emotional upset. Vascular tone dysfunction is 
mainly due to an impaired endothelial function. Several studies have demonstrated 
the reduction of flow-mediated dilation values supporting an impaired nitric oxide 
production 8. It must be pointed out that although it is mainly recognized at the 
digital level it is well established that all microcirculatory systems can be affected 
(heart, nose, gut) 4,5. By example, cardiac imaging showed abnormal perfusion 
related to small coronary artery disturbances after cold stress 7.  
With the progression of structural vascular changes, functional alteration of vascular 
cells includes endothelial apoptosis, impaired coagulation/fibrinolysis system, 
aberrant expression of soluble factors and cell adhesion molecules leading to the 
pathological inflammation. In this phase, perivascular infiltrates are evident, 
endothelial cells, pericytes and vascular smooth muscle cells proliferate, endoMT 
takes place and myofibroblast are activated in the dermal tissue 9. The next steps 
include altered neovascularization and vascular remodelling due to the impairment of 
compensatory vasculogenesis and exaggerated angiogenesis 10-16. Circulating 
levels of various angiogenic/angiostatic factors are largely altered and, so far, most of 
studies have revealed that pro-angiogenic factors are increased throughout the 
disease course, especially in the active stage of the disease 17, 18. The 
progression of these events leads to intima and media fibroproliferation which will 
provoke a microvessel obliteration. Consequently, chronic hypoxia may further 
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promote the fibrosis of the surrounding tissue 16. The early damage to the 
endothelium together with the vascular instability and the chronic hypoxia generating 
reactive oxygen species have thus a downstream deleterious effect on capillaries 
17. This leads eventually to an aberrant angiogenesis and progressively to a loss of 
capillaries. The vessel obliteration will further progress to tissue anoxia which will 
have a devastating effect on the extremities with tissue necrosis and gangrene 17. 
 Taken together, these findings support a generalised microvascular impairment in 
SSc. One may ask why the digits might be primarily affected but the exposure to cold 
of this body area is submitted to more important and/or earlier damages that could 
explain the high risk for the development of digital ischemia and ulceration. 
Nevertheless, the pathogenesis of the vasculopathy, the findings of abnormal 
circulating markers as previously highlighted, such as the inverse correlation of FMD 
values with pulmonary arterial pressure and the association of decreased FMD 
values with the presence of pulmonary arterial hypertension and digital ulcers, 
indicate the presence of a generalized vascular abnormality 19, 20. Therefore, the 
natural course of the disease should be evaluated more deeply to see whether the 
proliferative and obliterative vasculopathy may gradually and sometimes sub-
clinically progress along with disease duration, becoming eventually clinically evident 
with variable tonality of severe vessel involvement. This may thus lead to the periodic 
or recurrent DU, to pulmonary arterial hypertension (PAH), to heart failure and to 





RISK FACTORS AND VASCULARS COMPLICATIONS IN SSc PATIENTS 
HAVING DIGITAL ULCERS: DATA FROM CROSS-SECTIONAL STUDIES 
To investigate the vascular clinical manifestations occurring in patients with DU, the 
characteristics of SSc-DU patients versus the non-affected patients have been 
analysed in the report of large cross-sectional series.  
In a French multicentre study, the cross-sectional analysis of 599 patients with SSc, 
found that 53% had prior or current DU. Looking at associated variables, DU 
appeared to occur more frequently among males, patients with a higher Rodnan skin 
score, patients with early onset of disease, patients with carbon monoxide lung 
diffusion capacity (DLCO) < 60% predicted, and patients with anti-topo I antibodies. It 
must be highlighted that sex and skin disease were the strongest associated 
variables. The frequency of PAH was not higher in patients with prior or current DU 
than in those never affected 21. DLCO measures gas exchanges through the 
alveolar membrane and can be influenced by the thickness of the alveolar membrane 
and lung capillary volume. Therefore, a reduced DLCO in the absence of impairment 
in pulmonary function (FVC %) may represent a surrogate marker of vasculopathy. 
The association with DLCO impairment, the worsening of RP and the presence of 
recurrent DU indicate the pathophysiological link between the disease involvement of 
two different endothelial systems, that of the lung and the digits. However, no 
relationship between prior or current DU and PAH was observed in Tiev et al study.  
The German network has provided data derived from 1880 patients from whom 1690 
were evaluable for DU. Out of these, 408 (24%) had DU at the time of entering the 
registry. In multivariate analysis, datasets from 1164 patients were used and 
revealed that male sex was the most powerful independent predictor for the presence 
of DU and that PAH, anti-Scl70 antibodies (but not ACA), involvement of the mouth 
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or oesophagus, elevated erythrocyte sedimentation rate or onset of RP at young age 
were all risk factors for the presence of DU. Diffuse skin sclerosis in combination with 
PAH was the most powerful predictor for the occurrence of DU 22.  
In another national project, a total of 19 Spanish centres participated in the 
recruitment of 1326 SSc patients; of these, 552 SSc patients had prior or current DU. 
Multivariate analysis identified that history of prior/current DU in patients with SSc 
was independently associated to younger age at SSc diagnosis, diffuse cutaneous 
SSc, peripheral vascular manifestations such RP, telangiectasia, and acro-osteolysis 
23. However, history of DU was not associated with any visceral vasculopathy such 
as PAH or scleroderma renal crisis.  
The Canadian registry investigated the features associated with DU and their 
complications and made an effort to determine if DU were associated with PAH and 
scleroderma renal crisis (SRC). Among 938 SSc patients, 8% had a current DU, 44% 
had a digital ulcer ever, and 53% had digital pitting scars. In the multivariate analysis, 
the most important variables to predict DU were younger age of onset, ILD, higher 
hand and finger skin score, and higher HAQ score 24. There was no significant 
association between the history of DU and any definition of PAH (prevalence 
measured at 9%) and neither with renal crisis (prevalence of 5%).  
If microcirculation impairment is fundamental in SSc vasculopathy, large vessel 
disease may overlap and contribute to tissue sufferance, although the potential role 
of atherosclerosis in SSc vascular damage is still debated. A Japanese cross-
sectional study looked at 254 patients among whom 48 SSc patients had prior or 
current DU (19%). There were no multivariable analyses performed but it is of 
interest to point out that carotid atherosclerosis was not more common in patients 
with DU as compared to SSc patients without DU. Regarding SSc characteristics, DU 
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were more common in males, in DcSSs, mRSS was higher in patients with a history 
of DU confirming previous findings coming from other geographical populations 26. 
A focus was then done on heart disease, showing no more PAH in DU-SSc patients 
(9 vs 10% in DU-SSc versus non-DU-SSc). After exclusion of the PAH patients, 
those with DU had more commonly elevated natriuretic peptide or milder cardiac 
abnormalities such as EKG changes or coronary artery disease 25.  
Cutaneous telangiectasias are common in SSc and part of the ACR EULAR 
classification criteria. A cross-sectional study aimed at determining whether the 
number and size of cutaneous telangiectasia were associated with the pattern of 
microvascular lesions assessed by nailfold videocapillaroscopy (NVC) and markers 
reflecting the severity of SSc-related vasculopathy. Among total of 87 patients 
profuse and pseudotumoral cutaneous telangiectasia were both associated with 
capillary loss and severe dysangiogenesis on NVC 26. In multivariate analysis, 
profuse pseudotumoral cutaneous were independently associated with past or 
current digital ulcers whereas pseudotumoral cutaneous were independently 
associated with the late NVC pattern and PAH 28. Of the most interest, a previous 
study showed some association between telegiectasia and PAH with adjusted 
relative odds of PAH of 12 for patients with a 10-point increase in telangiectasia 
score 27. These 2 studies emphasize on telangiectasia being a potential clinical 
marker of more widespread aberrant microvascular disease in SSc. 
Regarding another vascular organ complication, there are few studies about the risk 
factors of renal crisis however, none did suggest so far that DU or PAH may be risk 
factors for such event 28.  
The results of the main above studies are summarized in Table 1 where associations 
observed in multivariable analyses are highlighted. Altogether, with the limitation of 
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their cross-sectional design, they show that DU are more common when SSc 
occurred earlier, in male patients, in those with DcSSc subset and high mRSS, but 
they do not show consistently higher risk of PAH, heart failure or renal crisis in DU 
patients as compared to non-DU patients.  
 
VASCULARS COMPLICATIONS IN SSc PATIENTS HAVING DIGITAL ULCERS: 
DATA FROM LONGITUDINAL STUDIES 
Another way to explore if DU may be a surrogate for generalized vasculopathy is to 
look at prospective data to see whether SSc patients with DU at baseline develop 
more organ vasculopathy than non-affected patients.  
A study looking at the natural history of SSc-DU was based on 103 patients among 
whom 46 had a history of DU. The mean duration of follow-up from the first non-
Raynaud SSc symptoms was about 12 years. In 43% of cases, the first DU occurred 
within 1 year following the first non-Raynaud SSc symptoms, and within 5 years in 
73% of cases. In multivariable analysis, younger patients at occurrence of first non-
Raynaud SSc symptoms and with higher skin score (such has being classified with a 
diffuse cutaneous subset) experienced earlier DU occurrences. It must also be 
pointed out that the first DU manifestation was delayed when vasodilator therapy was 
offered (mainly calcium channel blockers or ACE inhibitors). Pulmonary arterial 
hypertension (PAH) occurred in 11 patients (11%) during the course of the disease 
and its prevalence was comparable between the subgroups (14% PAH in the DU 
subgroup and 9% PAH in the no DU subgroup; p = 0.53) 29. 
One of the main studies that highlighted the link between DLCO and vasculopathy 
was based on Pittsburgh’s Scleroderma Databank from which 106 patients who had 
the diagnosis of PAH were matched with 106 controls by SSc skin subtype, age, sex, 
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race, disease duration, and the mean time to the diagnosis of PAH after the initial 
Pittsburgh visit. If a decline in DLCO pre-empted PAH, PAH patients and controls 
had a similar frequency of RP, digital tip ulcers, and digital gangrene. However, 
visual analogue scales for RP, showed that cases had significantly higher values for 
both the severity of RP and the severity of digital tip ulcers 30. 
In EULAR Scleroderma Trials and Research (EUSTAR) EUSTAR cohort it was 
showed that at the first visit, 1092/3196 patients had a history of DU (34%). Follow-
up at 3 years was the-cut-off time to look at the occurrence of complications 31. In 
multivariable analyses adjusting for age, gender and other parameters considered 
potentially significant, a history of DU was strongly predictive for the presence of DUs 
at prospective visits, but also for an elevated systolic pulmonary arterial pressure on 
heart ultrasound, for any cardiovascular event (new DUs, elevated echo-sPAP or left 
ventricular failure, and for death). Overt PAH could not be analyzed and there was no 
prediction for renal crisis 31.  
In the Australian PAH registry, among 1636 patients with SSc, 194 (12%) had PAH 
proven by right-heart catheter including 160 who were detected prospectively by 
screening. The study primarily looked at the outcomes of patients according to the 
screening programmes but the characteristics of SSc-PAH are detailed and analysed 
using univariate analyses. The data show that SSc patients with PAH were older, had 
longer disease duration from the first non- RP clinical manifestation, were more likely 
to be anti-centromere-positive and to have telangiectasia, calcinosis and joint 
contractures 32. Furthermore, DU were more frequent in PAH patients (53% in 
PAH-SSc patients and 42% in SSc non PAH patients) but the strength of association 
is not very strong and multivariable analyses would be required to determine 
independency in prediction.  
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The German network has also looked at prospective data regarding DU and showed 
various progression according to SSc characteristics. Unfortunately, no details were 
provided for other outcomes except for a statement that the weak or lack of 
association of DUs with pulmonary hypertension or heart and renal involvement 
indicates that the vasculopathy in digital arteries and the renal and pulmonary 
vasculature seem to be affected by different pathophysiological pathways 33.  
Conversely to the cross-sectional analyses, the available longitudinal data seem to 
support some links between baseline DU and the subsequent risk of more sevre 
vasculopathy defined by recurrent DU but also the risk of PAH. The low frequency of 
renal crisis and heart failure limits the possibility to identify such links but the large 
EUSTAR registry supports a predictive value of baseline DU for overall 
cardiovascular complications. Confirmation will have to be investigated in new 
extracts with more patients and longer follow-up. 
 
VASCULAR BIOMARKER STUDIES 
Many studies investigated in recent years candidate vascular biomarkers. While 
some were mainly descriptive using cross-sectional design, some others were based 
on longitudinal data allowing prediction of overall vascular risk 34.  
The pentraxins are a very conserved family of proteins with a unique architecture. In 
humans the two main members of this family are C-reactive protein and serum 
amyloid P.  Pentraxin 3 (PTX3) is expressed predominantly in atherosclerotic lesions 
that involve various cells such as macrophages, neutrophils, dendritic cells, or 
smooth muscle cells. Interestingly, PTX3 has been examined, as a novel biomarker 
for inflammatory cardiovascular disease. In SSc, circulating PTX3, but also fibroblast 
growth factor 2 (FGF-2) levels, have been found to be significantly higher in SSc 
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patients than in healthy control subjects 35. Of the most interest, PTX3 was 
elevated in SSc patients who had digital ulcers or PAH, while FGF-2 was reduced in 
SSc patients with PAH. Multivariate analysis identified elevated PTX3 as an 
independent parameter associated with the presence of DU and PAH. Furthermore, 
PTX3 levels were a useful predictor of future occurrences of digital ulcers and 
reduced FGF-2 was independently associated with the presence of PAH.  
Chemokine CXCL4 levels have been found to be correlated with skin and lung 
fibrosis and also with pulmonary arterial hypertension. No data were provided 
regarding DU. But among chemokines, only CXCL4 predicted the risk and 
progression of systemic sclerosis 36.  
Using a cohort of 100 patients and a follow-up of 3 years, vascular biomarkers of new 
events were investigated, primarily to predict the development of new DU that 
occurred in 17 SSc patients. Both angiogenic and vasculogenic markers were 
measured. Using various multivariable models, first the history of previous DU but 
also placenta growth factor (PlGF) levels and endothelial progenitor cell count were 
independent predictors of the development of DU 37. The prediction of other cardio-
vascular end-points were studied suggesting stimulating clues with these markers but 
the number of events was low which limited statistical power. Interestingly, another 
study confirmed the promise of PlGF and also of Flit1 as measures of pulmonary 
hypertension in SSc 38. 
Angiotensin II Type 1 receptor (AT1R) and endothelin 1 Type A receptor (ETAR) are 
functional autoantibodies directed against vascular receptors. A majority of SSc 
patients have increased levels of anti-AT1R and anti-ETAR antibodies compared to 
healthy donors. Moreover, in SSc patients, the auto-antibodies are associated with 
various vascular symptoms of the disease such as PAH, DUs, and renal crisis. 
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Nevertheless, the antibodies are also associated with the diffuse cutaneous subtype 
as well as with lung fibrosis. Altogether, these data suggest a possible role of the 
antibodies in disease mechanisms but their use in clinical practice for predicting 
damages remains to be established. In the context of DU, it has been shown that 
anti-ETAR autoantibodies can be used together with the presence of current or past 
DU to identify patients with SSc who are at risk for the development of subsequent 
DU 39, 40. 
Imaging may also provide some tools to predict DU and vascular outcomes. Few 
studies have been performed so far but capillaroscopy was found to be an interesting 
candidate and a prospective study of 6 months identified that the mean number of 
capillaries per millimeter in the middle finger of the dominant hand, the number of DU 
at enrolment, and the presence of critical digital ischemia at enrolment were risk 
factors for the development of new DUs. Other cardiovascular outcomes were not 
measured on that duration 41.  
The carotid-femoral pulse wave velocity (PWV) is a marker of aortic stiffness that 
holds prognostic significance in various vascular conditions, including systemic 
hypertension, renal failure and heart failure. The augmentation index (Aix_75), 
defined as the amplitude of the reflected wave from the periphery to the heart, can be 
measured by applanation tonometry and depends on several factors including large 
artery but also medium and small arteries stiffness. Radial applanation tonometry has 
been investigated in a group of 63 SSc patients to look for an association of PWV or 
Aix_75 with DU in 10 SSc patients. No differences existed in baseline characteristics 
between SSc-DU versus SSc-non DU patients, regarding cutaneous subset of the 
disease and disease duration, renal and pulmonary function, cardiovascular risk 
factors, heart function and pulmonary artery pressure 42. SSc patients with DU 
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versus those without had increased Aix_75 while there was no difference in PWV. 
The results of the multivariate logistic regression revealed that age, sex, erythrocyte 
sedimentation rate, aortic pulse pressure and DU were independently associated 
with Aix_75 42. Collectively these results suggest the existence of increased small 
and medium arteries stiffness in SSc patients with DU without significant aortic 
increased stiffness, when compared to SSc patients without DU. The predictive value 
of such tool on broader cardiovascular outcomes and in a larger population would be 
of interest.  
 
CONCLUSION 
Vascular injury and subsequent vascular dysfunction are among the earliest 
alterations in SSc and are considered to act within the initiating steps in SSc 
pathogenesis. Microcirculation impairment is the hallmark of the disease may also 
spread to larger vessels even if the reality of increased prevalence of atherosclerosis 
in SSc remains controversial. The process is undoubtedly generalized and all 
microvascular territories are affected. This is strongly supported by autopsy studies 
that showed lung and kidney vessels involvement despite the lack of any evidence of 
organ involvement [43]. Among all vascular complications, it is well known that DU 
are the most common clinical expression of an advanced vasculopathy. It remains 
unclear why this area is mostly affected although the permanent exposure to external 
stress might contribute to its severity. Some have speculated that DU could be a 
clinical marker of tissue damage (vascular and fibrotic changes), but the 
epidemiological studies do not clearly and reproducibly demonstrate a strong link 
between DU and other vascular complications. Indeed, cross-sectional studies show 
that SSc-DU patients have a more severe disease but there is no demonstration of 
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higher frequency of PAH or renal crisis. The longitudinal studies further support 
poorer outcomes of SSc-DU patients and some do suggest some predictive value of 
baseline DU for subsequent DU or even PAH or overall cardio-vascular 
complications. However, at the moment, several methodological issues preclude firm 
conclusion. Indeed, the definition of the events differs between the studies, the time 
of observation is usually not very long for PAH which is usually a late complication 
and because of the scarcity of major cardiovascular events, the sample size may be 
an issue.  
 Biomarker studies highlight the systemic component of vasculopathy and suggest 
some links between DU and PAH but it seems that additional further and potential 
regional factors might contribute to more severe remodelling in the fingers or in the 
lung or in the kidney. Auto-antibodies might contribute to these specificities and it is 
of interest to see that DU are more common in dcSSc and probably anti-
topoisomerase positive patients whereas anti-centromere antibodies are reproducibly 
found in SSc-PAH patients and that anti-RNA polymerase 3 antibodies are strong 
markers of renal crisis. The role of others and functional antibodies are interesting 
clues in this context.  
Regarding vascular SSc therapies, several PAH drugs are available in SSc-PAH but 
the drugs are given to patients who have already developed histologically very 
advanced vasculopathy. At a less severe stage, calcium channel blockers and 
iloprost are licenced for severe Raynaud’s and bosentan for the prevention of DU. 
Clinical trials have shown their respective beneficial effects but the duration of the 
trials are short with a relative small number of selected patients and therefore, effects 
on other vascular outcomes could not be reliably measured. Scarce data are 
available from long-term observational studies but few did suggest that long-term use 
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of iloprost may reduce vascular progression 44, 45 and that long-term use of 
calcium channel blockers could reduce heart or kidney progression 46, 47. 
Although such results could support a continuum in the vasculopathy, these data are 
very preliminary and cannot allow any definite conclusion.  
One might also add that the natural course of vasculopathy and its complications are 
moving in the recent years and the recent findings about DU recurrence showing 
faster healing and less relapse should stimulate further studies to assess vascular 
outcomes and management 48-50. Therefore, SSc-DU patients have worse 
outcomes than non-affected patients and they should be managed as patients having 
a severe form of the disease 51. However, the reason why vasculopathy may be 
mainly expressed in digital arteries in some patients and in pulmonary or kidney 
arteries in others remain unclear. Improving the knowledge in the field would distress 











Table 1: Digital ulcer associations through multivariable analyses in large multicentre 
















Definition of DU 
(and prevalence) 
Prior or current 
DU 
(53%) 






Prior or current 
DU (42%) 
Age  + - + + 
Male sex + ++ - - 
Smoking - Not studied - - 
Disease duration + - - - 
Severe skin 
involvement 
+ NA + (finger 
mRSS) 
- 
DcSSc - - - + 
Anti-
topoisomerase 
- + - - 
Erythrocyte 
sedimentation rate 
Not studied + - Not studied 
Esophageal 
involvement 
Not studied + +/- Not studied 
DLCO + 
(<60%) 
NA - - 
Interstitial lung 
disease 
(severe ILD is 
and exclusion 
criteria) 





+ - - 
Renal crisis - - - - 










Figure 1: Sources of information to answer the research question about the 
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